A preliminary study of transplantation of human umbilical cord mesenchymal stem cell in a rabbit model of intervertebral disc degeneration

Yanqiang WANG,Pengfei LV,Guangwu ZHANG,Mingchuan YU,Xiaolei TIAN,Zheng LIU

DOI: https://doi.org/10.3969/j.issn.1674-1439.2014.06-017

2014-01-01

Abstract:Background:A large amount of researches confirmed that bone marrow mesenchymal stem cells is able to differentiate into intervertebral disc cells both in vitro and in vivo, and preliminarily used for the treatment of intervertebral disc degeneration. Compared with bone marrow mesenchymal stem cells, human umbilical cord mesenchymal stem cells (UCMSCs) have ob-vious advantages:low cost, wide sources, not causing new trauma and pain for the donor, not involving ethical issues, stron-ger plasticity and amplification ability, non-tumorigenic activity and low-immunogenicity, no decrease of proliferation abili-ty or differentiation ability with passage number and body age increasing. <br> Objective:The purpose of the study is to evaluate whether injections of UCMSCs had regenerative effects on intervertebral disc degeneration in a rabbit model. <br> Methods:UCMSCs were cultured in vitro. Four continuous lumbar discs were injured by aspirating nucleus pulposus in rab-bits to induce disc degeneration and then the rabbits were treated by injection with UCMSCs or phosphate buffered saline (PBS). At 4, 8, and 12 weeks after initial injection, rabbits were performed by X-rays and magnetic resonance imaging (MRI), and ther they were sacrificed and the spine was extracted for detecting proteoglycan content. <br> Results:DHI (disc height index) and proteoglycan content showed significantly lower in the degenerated group as compared with the control group, while the MRI grade showed the opposite change at 4, 8, and 12 weeks after initial injection (P<0.05). DHI and proteoglycan content in the UCMSCs-injected group were significantly higher than those in the PBS-inject-ed group at 12 weeks after injection, but the MRI grade showed the opposite change (P<0.05). <br> Conclusions:The results of our study indicate that UCMSCs is a promising candidate for the treatment of the degenerative disc disease.